Scynexis (SCYX) EBT Margin Growth (1y) (2014 - 2026)
Powered by 
Analysis
Scynexis (SCYX) EBT Margin Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 1,045.00 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -16,571.00 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -153.00 |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | -571.00 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 553.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 4,709.00 |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1,911.00 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -2,328.00 |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -801,907.00 |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | -251,226.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -251,226.00 |
| Dec 31, 2025 | 51,712.00 |
| Sep 30, 2025 | -208,685.00 |
| Jun 30, 2025 | 145,964.00 |
| Mar 31, 2025 | -216,627.00 |
| Dec 31, 2024 | -11,626.00 |
| Sep 30, 2024 | -38,553.00 |
| Jun 30, 2024 | -205,741.00 |
| Mar 31, 2024 | 306,648.00 |
| Dec 31, 2023 | 61,166.00 |
| Sep 30, 2023 | 180,029.00 |
| Jun 30, 2023 | 110,170.00 |
| Mar 31, 2023 | -154,773.00 |
| Dec 31, 2022 | 395,925.00 |
| Sep 30, 2022 | -177,313.00 |
| Mar 31, 2022 | -142,047.00 |
| Jun 30, 2019 | -257,961.00 |
| Mar 31, 2019 | -703,438.00 |
| Dec 31, 2018 | -238,281.00 |
| Sep 30, 2018 | 29,062.00 |